WhiteLab Genomics
AI platform that designs and predicts molecular constructs for gene and RNA therapies before they reach the lab
ALFRED is worth a serious look if you're running a gene or RNA therapy program and your bottleneck is construct selection before synthesis. The May 2026 in vivo brain-delivery data is the strongest external evidence in this category — a vendor claim about CNS targeting is normally unverifiable in silico; in vivo IV data is not. It's built for teams with in-house computational biology and a therapeutic hypothesis, not for exploratory buyers. Compare against Geneious, Benchling, and in-house pipelines: those handle data management and sequence editing, ALFRED predicts construct performance. If you don't have biology staff to interpret the output, it won't help.
Verified 1h ago · liveness 56/100 · cite: rightaichoice.com/tools/whitelab-genomics
- Gene therapy R&D teams optimizing AAV capsids and promoters for CNS disease
- Pharma and biotech R&D groups de-risking genomic medicine programs
- Academic labs with computational biology staff working on viral vector engineering
- CROs supporting nucleic acid therapies that need in silico construct validation
- AI researchers without biology domain expertise
- Individual clinicians without lab or R&D resources
- Software developers with no genomics background
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip WhiteLab Genomics if you want a general-purpose sequence editor or bioinformatics data platform rather than construct prediction — ALFRED assumes you already have a therapeutic program and staff who can interpret capsid, promoter, and tropism predictions.
Bringing a new modality online — non-viral vectors or cell therapy after starting with AAV — typically means a scope change to the engagement rather than a toggle inside an existing plan.
WhiteLab sells to funded R&D organizations running gene or RNA therapy programs — pharma, established biotech, well-resourced academic groups, and CROs. That places it above self-serve sequence tools like Geneious or SnapGene on cost and below full discovery-platform contracts. Budget for the platform plus the computational biologist who runs it, not just the platform.
In short
WhiteLab Genomics — AI platform that designs and predicts molecular constructs for gene and RNA therapies before they reach the lab. Best for Gene therapy R&D teams optimizing AAV capsids and promoters for CNS disease, Pharma and biotech R&D groups de-risking genomic medicine programs, Academic labs with computational biology staff working on viral vector engineering. Contact Sales pricing.
What people actually say about WhiteLab Genomics — is it worth it?
We ran a structured research pass across product reviews, community discussions, and post-purchase forum threads to surface the patterns vendors won't publish themselves. Below: the recurring strengths, the hidden costs people mention most, and the cohort that consistently regrets adopting this tool.
5 mentions across 1 source (YouTube) · researched Aug 4, 2026.
Average across the 1 source that answered — each source counts once, not each post.
- +AI-driven design for AAV capsids, promoters, and guide RNAs improves accuracy.
- +Partnerships with Sanofi, Cytiva, and Debiopharm validate technology.
- +Covers multiple modalities: AAV, lentivirus, and nanoparticles.
- +In vivo brain delivery demonstration is a significant milestone.
- +In silico validation reduces costly trial-and-error in the lab.
- −Lack of independent user reviews undermines trust and assessment.
- −No transparent pricing; requires contact, which may deter small labs.
- −Advanced skill level needed; not accessible to beginners.
- −No mention of integrations or API, limiting workflow flexibility.
- −Proprietary datasets may lead to model bias or lack of transparency.
- • Likely requires a long-term contract and annual commitment
- • Potential additional fees for training and onboarding
Viability Score
How well maintained and how widely used is WhiteLab Genomics? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: October 2026
How we score →Key Features
- AI-designed AAV capsid variants with novel tropisms
- Promoter optimization for cell-type specificity
- Guide RNA design for CRISPR and gene editing therapies
- Off-target prediction for gene editing
- Toxicity prediction for molecular constructs
- Delivery vehicle optimization across AAV, lentivirus, and nanoparticles
- Target receptor identification for viral vectors
- Payload design for gene and RNA-based therapies
- Non-viral vector design for solid tumors and in vivo CAR-T
- Cell therapy support including CAR design
- Bioproduction optimization for AAV and lentivirus programs
- In silico construct validation before synthesis
- In vivo validated AI-designed vectors for CNS brain delivery after IV injection
- Collaborative project workspaces for computational and wet-lab teams
- Access to proprietary curated biological datasets
About WhiteLab Genomics
WhiteLab Genomics builds ALFRED, a computational platform that predicts and optimizes molecular constructs for genomic medicines. It combines curated biological data, rational design rules, and machine learning to work across modalities including AAV, lentivirus, and nanoparticles. You use it to identify target receptors for viral vectors, design novel AAV capsids with specific tropisms, optimize promoters for cell-type specificity, design guide RNAs and payloads, predict off-target and toxicity risk, and optimize bioproduction of AAV and lentivirus. Non-viral vector design and cell therapy work — including CAR design — are supported too, which matters for solid tumor and in vivo CAR-T programs. Founded in 2019 and backed by Y Combinator, WhiteLab has partnered with Sanofi, Debiopharm, Cytiva, Siren Biotechnology, Généthon, INSERM, Institut Imagine, and Institut de la Vision. In May 2026 the company presented in vivo data showing targeted brain delivery after IV injection using AI-designed vectors — a meaningful proof point for CNS gene therapy. The platform runs through collaborative project workspaces, so wet-lab and computational teams work from the same construct record.
Behind the Verdict
The case for WhiteLab rests on a specific claim: that in silico construct prediction can save you the cycles you currently burn on iterative wet-lab screening. The May 2026 in vivo data for AI-designed vectors achieving brain delivery after IV injection is the kind of evidence that claim needs, and it's the reason this tool is on the map for CNS programs specifically. The applications page shows where they're actually deployed — CNS (77%), ophthalmology (77%), rare disease (56%), oncology (56%), solid tumor non-viral (77%), in vivo CAR-T (77%), bioproduction across AAV and LV (80%), and cell therapy CAR design plus vectors (40%). Those percentages are the vendor's own collaboration-weighted figures, so treat them as a deployment map rather than a benchmark. Where ALFRED is genuinely differentiated is the coupling of construct design to a curated biological dataset and to bioproduction constraints — designing an AAV capsid that also manufactures well is a real problem and most design tools ignore it. The partner roster is a signal: Sanofi, Debiopharm, Cytiva, Siren Biotechnology, Généthon, INSERM, Institut Imagine, Institut de la Vision. These are groups with the internal expertise to evaluate the platform, not buyers who signed off on a demo. What you should weigh against that: ALFRED is deeply domain-specific, so the learning curve runs through your computational biology team, not through a generalist. Non-biologists will find it opaque — the vocabulary is capsids, tropisms, podocytopathies, and SURF1 Leigh syndrome, not prompts and templates. The collaboration model is project workspaces, which fits pharma R&D structures but isn't a plug-in for your existing LIMS without work. And the honest gap is that this is enterprise software sold to enterprise R&D organizations; if you're an academic lab or a pre-seed startup without a computational biology hire, the value proposition is thinner than the science. The UMass Chan case on the homepage is instructive: they found cytotoxicities with a first-version SURF1 Leigh syndrome therapy and spent three more years trialing promoters. That's the exact cost ALFRED is claiming to compress — and it's a plausible claim when the platform covers promoter optimization and toxicity prediction together. Where it doesn't fit: generalist AI researchers, bioinformatics tool-shopping without a therapeutic program, and anyone looking for a low-commitment evaluation.
Researching WhiteLab Genomics? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas WhiteLab Genomics actually fits — and what changes day-one when you adopt it.
You need a capsid that crosses into the brain after IV injection, and your current serotype doesn't. You bring your target cell type and receptor hypothesis into ALFRED, generate candidate capsid variants and rank them by predicted tropism, shortlist the top designs, then order them for in vivo testing in your mouse model.
Outcome: You enter the lab with a ranked shortlist instead of a random library, cutting the number of animals and synthesis cycles needed to find a lead capsid.
Your team previously spent years trialing promoters after hitting cytotoxicity with a first-version construct. You use ALFRED's promoter optimization and toxicity prediction together to design and filter a promoter-construct combination that is both specific and tolerable before anything gets synthesized.
Outcome: Toxicity and specificity problems surface in silico rather than after months of bench work, and you carry a documented design rationale into your regulatory discussions.
A capsid that performs in vivo is underproducing in your bioreactor. You run the construct through ALFRED's bioproduction optimization, compare variants on manufacturability alongside efficacy, and pick a design that holds up on both axes.
Outcome: You avoid the cycle of optimizing a vector for delivery and then rebuilding it for production yield, which is a common cause of timeline slip before IND.
Use Cases
- Design AAV capsids with tropisms for cell types that current vectors cannot reach
- Predict construct toxicity before committing to synthesis and animal work
- Choose a promoter that gives cell-type-specific expression for a CNS or retinal program
- Optimize guide RNA sequences for on-target efficiency and reduced off-target editing
- Model delivery vehicles for mRNA and other RNA-based therapies
- Develop CNS-targeted gene therapies with vectors already demonstrated in vivo after IV injection
- Optimize AAV and lentivirus bioproduction to reach clinical and regulatory milestones faster
- Design CAR constructs and vectors for cell therapy programs
Limitations
- ALFRED is deeply specialized in genomic medicine — you need in-house computational biology or vector engineering expertise to interpret capsid, tropism, and promoter output.
- The platform is organized around project workspaces rather than a general data-management suite, so it complements rather than replaces a benchling-style registry or LIMS.
- Vendor-published deployment coverage figures for therapeutic areas and modalities are collaboration-weighted and should be read as a map of where the platform has been used, not as benchmark accuracy.
as of 2026-10-08
Verification history
We have re-verified WhiteLab Genomics 8 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Showing the 6 most recent of 8 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where WhiteLab Genomics's pricing actually pencils out — and where peers do it cheaper.
WhiteLab sells to funded R&D organizations running gene or RNA therapy programs — pharma, established biotech, well-resourced academic groups, and CROs. That places it above self-serve sequence tools like Geneious or SnapGene on cost and below full discovery-platform contracts. Budget for the platform plus the computational biologist who runs it, not just the platform.
Setup time & first value
How long it actually takes to get something useful out of WhiteLab Genomics — broken out by persona, not the marketing-page minute.
Expect weeks, not days, to first useful output. The onboarding work is getting your target cell types, receptor hypotheses, and construct parameters into ALFRED and agreeing with the vendor on which programs to run first. Teams with in-house computational biology and clean internal sequence data get to a first ranked construct fastest; teams without that staff spend the early period building the
Switching to or from WhiteLab Genomics
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From manual capsid screening: bring your existing capsid library and tropism results into ALFRED and use them as the training context for the next design round.
- →From in-house sequence pipelines: keep your existing data store and route design questions to ALFRED rather than rebuilding prediction models yourself.
- →From spreadsheets of promoter and construct variants: consolidate variant records into ALFRED project workspaces so computational and wet-lab teams work from the same construct record.
- →From a prior CRO design engagement: use ALFRED to bring design iteration back in-house while keeping wet-lab validation with your CRO.
- ↗To a full data-management platform: export construct and design records into your registry of record, since ALFRED is organized around design projects rather than being a LIMS replacement.
- ↗To in-house models: if you build internal prediction models, your ALFRED design history becomes the training set and benchmark to compare against.
Resources & Guides
Tutorials & Learning
YouTube returned 6 videos for “WhiteLab Genomics”, and we withheld 6: 6 did not mention WhiteLab Genomics. We are showing none, because we could not prove any of them are about WhiteLab Genomics.
Official links
Tools that pair well with WhiteLab Genomics
Common stack mates teams adopt alongside WhiteLab Genomics, with the specific reason each pairing earns its keep.
AminoAnalytica
AI and computational bionanotechnology R&D partnership that designs field-ready molecular diagnostics for emerging biological threats in days, not 12+ months.
Insilico Medicine
Generative AI drug discovery suite covering target ID, molecule design, biologics engineering and clinical trial prediction.
Iktos
Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.
Featured Head-to-Head Comparisons
Whitelab Genomics vs Codametrix
These tools serve completely different domains: CodaMetrix is for revenue cycle leaders in large health systems to automate medical coding, with proven 5:1 ROI and #1 KLAS ranking; WhiteLab Genomics is for gene therapy researchers designing DNA/RNA constructs. Buyers should choose based on their workflow—coding or genomic R&D—as there is no overlap.
Whitelab Genomics vs Rapidsos
Choose RapidSOS if your focus is public safety and emergency response with AI-enhanced dispatch and live data integration. Choose WhiteLab Genomics if you are in gene therapy R&D and need AI-driven optimization of AAV capsids, promoters, or guide RNAs. They are incomparable in domain, so decision depends entirely on your sector.
Whitelab Genomics vs Isomorphic Labs
If you need AI-guided design for gene therapy constructs (capsids, promoters, guides) with in silico validation and collaborative workspaces, WhiteLab Genomics is the targeted choice. For large-scale small molecule drug discovery powered by AlphaFold and deep pharma partnerships, Isomorphic Labs is the more powerful but less accessible platform. Choose based on whether your focus is genomic medicine or traditional small molecule drug development.
Alternatives to WhiteLab Genomics
View all
AminoAnalytica
AI and computational bionanotechnology R&D partnership that designs field-ready molecular diagnostics for emerging biological threats in days, not 12+ months.
Insilico Medicine
Generative AI drug discovery suite covering target ID, molecule design, biologics engineering and clinical trial prediction.
Frequently Asked Questions
Categories
Used WhiteLab Genomics? Help shape our editorial sentiment research.